HTG MOLECULAR DIAGNOSTICS (HTGM)

Company Profile

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. The company is headquartered in Tucson, Arizona and currently employs 53 full-time employees. The company went IPO on 2015-05-06. The firm is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The firm is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.

Company Info

HTG MOLECULAR DIAGNOSTICS

3430 E Global Loop

Tucson ARIZONA 85706

P: 18772892615.0

CEO: John L. Lubniewski

Employees: 53

Website: https://www.htgmolecular.com/